Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 7/20 | 0.44 |
| ▸ | CDK9 | P50750 | 7/20 | 0.44 |
| ▸ | CDK2 | P24941 | 6/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | FGR | P09769 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.41 |
| ▸ | ABL2 | P42684 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15464143 | 0.98 | CCNT1 (0.45) | CCNT1CDK9CDK2CCNE1KCNH2 | |
| SCHEMBL28036711 | 0.81 | CYP1A1 (0.51) | CYP2D6 | |
| SCHEMBL174453 | 0.78 | CYP1A2 (0.54) | CYP2D6 | |
| SCHEMBL14062164 | 0.78 | CCNT1 (0.50) | CCNT1CDK9CDK2CCNE1CCNE2 | |
| SCHEMBL532852 | 0.76 | SCN9A (0.36) | SCN9A | |
| SCHEMBL11425087 | 0.74 | CYP11B1 (0.55) | CDK2KCNH2GSK3BCYP2D6GRIN2B | |
| SCHEMBL30777916 | 0.71 | CYP1A2 (0.48) | CCNT1CDK9KCNH2CYP2D6 | |
| SCHEMBL2812677 | 0.71 | ALDH1A1 (0.51) | CCNT1CDK9CDK2CCNE1KCNH2 | |
| SCHEMBL8514899 | 0.71 | CYP1A2 (0.48) | CCNT1CDK9KCNH2CYP2D6 | |
| SCHEMBL27939192 | 0.71 | KCNH2 (0.43) | CCNT1CDK9CDK2KCNH2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180050040-A1 | USE OF 4-(4-FLUORO-2-METHOXYPHENYL)-N--1,3,5-TRIAZIN-2-AMINE FOR TREATING LYMPHOMAS | Bayer Pharma AG (DE) | 2018-02-22 | — | — | US | disclosed |
| US-20170368069-A1 | USE OF 4-(4-FLUORO-2-METHOXYPHENYL)-N--1,3,5-TRIAZIN-2-AMINE FOR TREATING LEUKEMIAS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368069-A1 | USE OF 4-(4-FLUORO-2-METHOXYPHENYL)-N--1,3,5-TRIAZIN-2-AMINE FOR TREATING LEUKEMIAS | MCL1, ABL1, NPM1 | CCNT1 1004/4885CDK9 896/4885CDK2 384/4885 |
| US-20180050040-A1 | USE OF 4-(4-FLUORO-2-METHOXYPHENYL)-N--1,3,5-TRIAZIN-2-AMINE FOR TREATING LYMPHOMAS | MALT1, BCL6, BCL3 | CCNT1 260/4885CDK9 1445/4885CDK2 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.